Lazard Asset Management
LXRX icon

Lazard Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Lazard Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,090
Closed -$16.2K – 2001
2025
Q4 		$16.2K Buy
+14,090
New +$19.4K ﹤0.01% 1835
2020
Q4 		– Sell
-1,753,445
Closed -$2.52M – 1919
2020
Q3 		$2.52M Buy
1,753,445
+997,103
+132% +$1.78M ﹤0.01% 694
2020
Q2 		$1.51M Buy
+756,342
New +$1.48M ﹤0.01% 715
2020
Q1 		– Sell
-5,600
Closed -$23K – 1663
2019
Q4 		$23K Buy
+5,600
New +$21.6K ﹤0.01% 1201
2019
Q1 		– Sell
-45,200
Closed -$300K – 1181
2018
Q4 		$300K Buy
+45,200
New +$366K ﹤0.01% 833
2016
Q2 		– Sell
-147,384
Closed -$1.76M – 1078
2016
Q1 		$1.76M Buy
147,384
+21,426
+17% +$225K ﹤0.01% 620
2015
Q4 		$1.68M Buy
125,958
+119,458
+1,838% +$1.47M ﹤0.01% 644
2015
Q3 		$69K Buy
+6,500
New +$71K ﹤0.01% 900

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Lazard Asset Management's LXRX Position: Q1 2026 in Review

Lazard Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 14,090 shares — an estimated $16.2K sold.

Lazard Asset Management first reported a position in LXRX in Q3 2015 and held it in 8 quarters. The position peaked at $2.52M in Q3 2020. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Lazard Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 14,090 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $16.2K.
  • Lazard Asset Management first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 8 quarters.
  • Lazard Asset Management's Lexicon Pharmaceuticals position peaked at $2.52M in Q3 2020.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.